Skip to content

Author

L. Rauschenbach

We have 3 of 136 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Carotid atherosclerotic disease in aneurysmal subarachnoid hemorrhage: an underrated risk for cerebral infarction.

OBJECTIVE Carotid atherosclerotic disease (CAD), which commonly results in internal carotid artery (ICA) stenosis, is a risk factor for ischemic stroke due to cerebral hypoperfusion. The aim of this study was to analyze the predictive value of CAD for the occurrence of infarction and an unfavorable outcome after aneury...

Adrian Engel, L. Rauschenbach, J. Rodemerk et al. · 0 citations
Review Open access Sep 2026

Machine learning models for adverse drug reaction prediction. A systematic review and three-level multilevel meta-analysis

Background Adverse drug reactions (ADRs) are a leading cause of preventable hospitalization, yet the dominant pharmacovigilance paradigm remains reactive. Machine learning (ML) offers a data-driven alternative, but the evidence base has not been formally meta-analyzed under clinically realistic inclusion criteria and a...

G. Cappello, C. Oster, T. Schmidt et al. · 0 citations
Open access Aug 2026

PDCD10-Deficient Tumor Cells Reprogram Angiogenesis Through Paracrine Endothelial Activation and GSC-like Plasticity in GBM

It is demonstrated that PDCD10 loss promotes GBM neo-angiogenesis involving complementary paracrine and GSC-like plasticity mechanisms, highlighting PDCD10 as a potential therapeutic target to suppress neo-angiogenesis in GBM.

Zhong-Rong Chen, Zhen Chen, Xue Wan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.